InflaRx N.V.
InflaRx N.V. (IFRX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Jena, Germany and has 65 employees. The company is worth $194.53M. Revenue was €29.33K in fiscal 2025, down 82.3% from the year before. It reported a net loss of €45.63M. The share price is 55.2% below its 52-week high of $2.95. 3 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $1.27M. In that quarter, 1 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Revenue, debt and profit are in EUR, the currency the company reports in — not converted to dollars. Dividends are in dollars.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -73.7% over 5Y.
today you would have $311.32▼ -68.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.01 | $2.47 | $1.63 | $3.10 | |
| EPS | -€0.68 | -€0.78 | -€0.78 | -€0.67 | |
| Profit margin | -67630.69% | -155582.08% | -27784.96% | -67630.69% | — |
| ROE | -58.30% | -109.81% | -75.00% | -41.59% | -33.37% |
This company reports in EUR, and the stock trades in dollars. P/E, P/S, P/B and payout would divide dollars by EUR, so they are not shown; EPS is in EUR. Margin, ROE and dividend yield do not depend on the currency.
Median of the years shown; P/E years above 200x are left out.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| FOCLEdap Tms SA | $4.09 | — | — | 0.00% | -265.67% | $193.12M |
| CAMPCamp4 Therapeutics Corp | $3.17 | — | — | 0.00% | -545.85% | $198.93M |
| LYELLyell Immunopharma, Inc. | $8.12 | — | 0.8x | 0.00% | -93.28% | $198.98M |
| RNACCartesian Therapeutics, Inc. | $6.27 |
| — |
| — |
| 0.00% |
| — |
| $189.7M |
| PYXSPyxis Oncology, Inc. | $1.68 | — | 9.3x | 0.00% | -179.10% | $200.69M |
| PDEXPro Dex Inc | $58.26 | 14.1x | 3.9x | 0.00% | 32.43% | $188.37M |